Nora Janjan, MD, MPSA, MBA | Authors

Oncology Peer Review On-The-Go: Academic Promotion and Oncology Drug Development

June 21, 2022

Nora Janjan, MD, MPSA, MBA, spoke with CancerNetwork® about the latest perspective from the journal ONCOLOGY® on how roles and responsibilities of academic clinicians in reporting of conflicts of interest influence oncology research.

Academic Promotion and Oncology Drug Development: Role, Responsibilities, and Integrity

February 18, 2022

Nora Janjan, MD, MPSA, MBA, gives her perspective on oncology drug development through academic promotion, as an accompaniment to the article titled "Association of Financial Conflicts of Interest With Academic Productivity Among Junior Faculty in Hematology and Oncology" published in the journal ONCOLOGY.

Management of Pain

June 01, 2015

Most patients with advanced cancer, and up to 60% of patients with any stage of the disease, experience significant pain. The WHO estimates that 25% of all cancer patients die with unrelieved pain.

Assumption of Risk, Healthcare Policy, and Cancer Screening

November 15, 2014

American medicine is poised for an expanded conflict over the assumption and consequences of risk in medical care.

The Risks of Undiagnosed Cancer vs the Theoretical Risks of Radiation Exposure

March 15, 2014

The Hippocratic Oath underscores that harm to patients can result either from acts of commission or omission. Decisions about the use of diagnostic imaging are now under great scrutiny.

Value Judgments in Diagnostic Imaging for Prostate Cancer: A Paradox in Healthcare Reform

April 15, 2013

Only the possibility of increasing survival with better tumor localization and staging is probable with multiparametric MRI-and improved survival with MR imaging in prostate cancer has not been shown in a clinical trial or meta-analysis to date.

Clinical Trials Need to Control for the Influence of Palliative Care on Outcomes

January 15, 2013

To insure standardization of all aspects of care during the conduct of a clinical trial, clinical trials should include guideline-based criteria for the management of all symptoms of cancer and its treatment, and failure to adhere to any of the standards for symptom management during the conduct of the trial should result in an equal level of protocol violation.

This Accelerates the Path to a Single-Payer System

June 29, 2012

This will have a significant impact on medicine and on the care we will be able to deliver. It has life and death implications. The patients of America, who have enjoyed the best healthcare in the world, have lost.

25 Years Later: Endangered Species or Successful Evolution?

December 16, 2011

While ONCOLOGY has continued to evolve along with the field of oncology-for example, it now addresses critical issues of science and socioeconomics-it has remained true to the founding principles. Perhaps largely for this reason, the journal continues to be widely read across the entire oncology community.